Blutungskomplikationen unter oraler Antikoagulation

J. Beyer-Westendorf

doi:10.1055/s-0034-1387393

DMW – Klinischer Fortschritt, Table of Contents

Dtsch Med Wochenschr 2014; 139(49): 2491-2493
DOI: 10.1055/s-0034-1387393

Angiologie | Commentary

Angiologie

Blutungskomplikationen unter oraler Antikoagulation

Bleeding complications under oral anticoagulation

J. Beyer-Westendorf

¹Bereich Angiologie, Universitäts GefäßCentrum, Universitätsklinikum Carl Gustav Carus der Technischen Universität Dresden

› Author Affiliations

Abstract

Full Text

References

Literatur
1 Beyer-Westendorf J, Forster K, Pannach S et al. Rates, management and outcome of bleeding complications during rivaroxaban therapy in daily care: results from the Dresden NOAC registry. Blood 2014;
2 Beyth RJ, Quinn LM, Landefeld CS. Prospective evaluation of an index for predicting the risk of major bleeding in outpatients treated with warfarin. Am J Med 1998; 105: 91-99
3 Dowlatshahi D, Butcher KS, Asdaghi N et al. Poor prognosis in warfarin-associated intracranial hemorrhage despite anticoagulation reversal. Stroke 2012; 43: 1812-1817
4 Gitter MJ, Jaeger TM, Petterson TM et al. Bleeding and thromboembolism during anticoagulant therapy: a population-based study in Rochester, Minnesota. Mayo Clin Proc 1995; 70: 725-733
5 Gomes T, Mamdani MM, Holbrook AM et al. Rates of hemorrhage during warfarin therapy for atrial fibrillation. Cmaj 2013; 185: E121-127
6 Halbritter K, Beyer-Westendorf J, Nowotny J et al. Hospitalization for Vitamin-K-Antagonist-related bleeding – treatment patterns and outcome. J Thromb Haemost 2013; 11: 651-659
7 Hylek EM, Held C, Alexander JH et al. Major bleeding in patients with atrial fibrillation receiving apixaban or warfarin: The ARISTOTLE Trial (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation): Predictors, Characteristics, and Clinical Outcomes. J Am Coll Cardiol 2014; 63: 2141-2147
8 Koscielny J, Beyer-Westendorf J, von Heymann C et al. [Risk of bleeding and haemorrhagic complication with rivaroxaban – periprocedural management of haemostasis]. Hamostaseologie 2012; 32: 287-293
9 Linkins LA, Choi PT, Douketis JD. Clinical impact of bleeding in patients taking oral anticoagulant therapy for venous thromboembolism: a meta-analysis. Ann Intern Med 2003; 139: 893-900
10 Majeed A, Hwang HG, Connolly SJ et al. Management and outcomes of major bleeding during treatment with dabigatran or warfarin. Circulation 2013; 128: 2325-2332
11 Piccini JP, Garg J, Patel MR et al. Management of major bleeding events in patients treated with rivaroxaban vs. warfarin: results from the ROCKET AF trial. Eur Heart J 2014;
12 Steffensen FH, Kristensen K, Ejlersen E et al. Major haemorrhagic complications during oral anticoagulant therapy in a Danish population-based cohort. J Intern Med 1997; 242: 497-503
13 Steiner T, Bohm M, Dichgans M et al. Recommendations for the emergency management of complications associated with the new direct oral anticoagulants (DOACs), apixaban, dabigatran and rivaroxaban. Clin Res Cardiol 2013; 102: 399-412
14 Willey VJ, Bullano MF, Hauch O et al. Management patterns and outcomes of patients with venous thromboembolism in the usual community practice setting. Clin Ther 2004; 26: 1149-1159